{"id":10310,"date":"2025-11-27T18:00:07","date_gmt":"2025-11-27T17:00:07","guid":{"rendered":"https:\/\/www.biont.sk\/?p=10310"},"modified":"2025-11-27T18:41:03","modified_gmt":"2025-11-27T17:41:03","slug":"18f-fluoroestradiol","status":"publish","type":"post","link":"https:\/\/www.biont.sk\/18f-fluoroestradiol\/","title":{"rendered":"[18F]-Fluoroestradiol"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"10310\" class=\"elementor elementor-10310\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-297b795 e-flex e-con-boxed e-con e-parent\" data-id=\"297b795\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3c0dd5f elementor-widget elementor-widget-text-editor\" data-id=\"3c0dd5f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Liek [<sup>18<\/sup>F]-Fluoroestradiol Biont vyr\u00e1ba spolo\u010dnos\u0165 BIONT a. s. a\u00a0bude sa pou\u017e\u00edva\u0165 v\u00fdhradne v mieste v\u00fdroby \u2013 v\u00a0zdravotn\u00edckom zariaden\u00ed firmy BIONT, a. s. v\u00a0Bratislave, nako\u013eko m\u00e1 s\u00fahlas MZ SR na skupinov\u00e9 povolenie neregistrovan\u00e9ho lieku.<\/p><p><strong>[<sup>18<\/sup>F]-Fluoroestradiol Biont (FES)<\/strong> je ur\u010den\u00fd pre diagnostiku v nukle\u00e1rnej medic\u00edne,\u00a0 ktor\u00e1 umo\u017e\u0148uje neinvaz\u00edvne in-vivo pos\u00fadi\u0165 <strong>expresiu estrog\u00e9nov\u00fdch receptorov (ER) n\u00e1dorov\u00fdmi bunkami <u>karcin\u00f3mu prsn\u00edka.<\/u> <\/strong><\/p><p>Met\u00f3da PET\/CT s [<sup>18<\/sup>F]-flu\u00f3rdeoxygluk\u00f3zou (FDG), referen\u010dn\u00fdm r\u00e1diofarmakom v\u00a0onkol\u00f3gii, je \u0161tandardne pou\u017e\u00edvan\u00e1 vo viacer\u00fdch klinick\u00fdch indik\u00e1ci\u00e1ch z\u00e1kladn\u00e9ho ochorenia, pri r\u00f4znych histologick\u00fdch form\u00e1ch karcin\u00f3mu prsn\u00edka. U\u00a0dobre diferencovan\u00fdch foriem karcin\u00f3mu prsn\u00edka m\u00f4\u017ee ma\u0165 limitovan\u00fd pr\u00ednos.<\/p><p><strong>FES sa v onkol\u00f3gii prsn\u00edka uplat\u0148uje v \u0161pecifickej diagnostike a zobrazovan\u00ed n\u00e1dorov s vysokou expresiou ER<\/strong>. \u0160pecificky sa via\u017ee na estrog\u00e9nov\u00e9 receptory, a t\u00fdm priamo zobrazuje ER-pozit\u00edvne n\u00e1dory, \u010do je ve\u013emi d\u00f4le\u017eit\u00e9 pri pl\u00e1novan\u00ed a sledovan\u00ed lie\u010dby hormon\u00e1lne citliv\u00fdch foriem karcin\u00f3mu prsn\u00edka.<\/p><p>V porovnan\u00ed s FDG, ktor\u00fd je gluk\u00f3zov\u00fdm anal\u00f3gom zobrazuj\u00facim metabolick\u00fa aktivitu buniek v\u0161eobecne, FES poskytuje vy\u0161\u0161iu \u0161pecifickos\u0165 a diagnostick\u00fa presnos\u0165 pri ER-pozit\u00edvnom karcin\u00f3me prsn\u00edka, najm\u00e4 u n\u00e1dorov s vysokou expresiou ER. Navy\u0161e FES pom\u00e1ha lep\u0161ie odl\u00ed\u0161i\u0165 menej agres\u00edvne, ER-pozit\u00edvne typy (napr. luminal A) od agres\u00edvnej\u0161\u00edch s ni\u017e\u0161ou alebo negat\u00edvnou ER expresiou, kde FDG vykazuje vy\u0161\u0161iu senzitivitu aj \u0161pecificitu. <strong>Stanovenie ER statusu je d\u00f4le\u017eitou inform\u00e1ciou, ktor\u00e1 m\u00e1 rozhoduj\u00faci vplyv na vo\u013ebu terapie a doteraz ho bolo mo\u017en\u00e9 vykona\u0165 iba invaz\u00edvne, bioptick\u00fdm vy\u0161etren\u00edm<\/strong>. Biopsie v\u0161ak nie je mo\u017en\u00e9 realizova\u0165 z v\u00e4\u010d\u0161ieho po\u010dtu metast\u00e1z alebo opakovane, \u010d\u00edm sa st\u00e1va ER status nedostupn\u00fdm pre klinick\u00fd rozhodovac\u00ed proces.<\/p><p><strong>PET\/CT s [<sup>18<\/sup>F]-Fluoroestradiolom je bezpe\u010dnou a efekt\u00edvnou alternat\u00edvou k bioptick\u00fdm met\u00f3dam, ktor\u00e1 umo\u017en\u00ed detailnej\u0161\u00ed poh\u013ead do biol\u00f3gie karcin\u00f3mu prsn\u00edka a napom\u00f4\u017ee individualizovan\u00e9mu pl\u00e1novaniu lie\u010dby pacientov.<\/strong><\/p><p><strong><em><u>Hlavn\u00fdmi indik\u00e1ciami PET\/CT vy\u0161etrenia s [<sup>18<\/sup>F]-Fluoroestradiol Biont s\u00fa:<\/u><\/em><\/strong><\/p><ul><li><strong><em>stanovenie inici\u00e1lneho \u0161t\u00e1dia a restaging ER pozit\u00edvneho karcin\u00f3mu prsn\u00edka<\/em><\/strong><\/li><li><strong><em>podozrenie na zmenu ER statusu pri progresii ochorenia, <\/em><\/strong><\/li><li><strong><em>stanovenie heterogenity expresie ER receptorov v prim\u00e1rnom n\u00e1dore a jeho metast\u00e1zach, <\/em><\/strong><\/li><li><strong><em>pos\u00fadenie vhodnosti hormon\u00e1lnej terapie. <\/em><\/strong><\/li><\/ul><p>Systematick\u00e9 metaanal\u00fdzy pr\u00ednosu PET\/CT vy\u0161etrenia s [<sup>18<\/sup>F]-Fluoroestradiol potvrdili vysok\u00fa senzit\u00edvnos\u0165 a \u0161pecifickos\u0165 met\u00f3dy v navrhovan\u00fdch indik\u00e1ci\u00e1ch. Klinick\u00e9 pou\u017eitie lieku je definovan\u00e9 v medzin\u00e1rodn\u00fdch odpor\u00fa\u010daniach Eur\u00f3pskej asoci\u00e1cie nukle\u00e1rnej medic\u00edny \/Spolo\u010dnosti pre nukle\u00e1rnu medic\u00ednu a molekul\u00e1rne zobrazovanie z roku 2023. Je s\u00fa\u010das\u0165ou diagnostick\u00fdch met\u00f3d uveden\u00fdch v odpor\u00fa\u010daniach NCCN (National Comprehensive Cancer Network, USA) pre lie\u010dbu karcin\u00f3mu prsn\u00edka od roku 2023.<\/p><p><strong>Klinick\u00e9 odpor\u00fa\u010dania:<\/strong><\/p><ul><li>Ulaner, G. A., et al. (2023).\u00a0<strong>Summary: Appropriate Use Criteria for Estrogen Receptor\u2013Targeted PET Imaging with 16\u03b1-18F-Fluoro-17\u03b2-Fluoroestradiol<\/strong>. Journal of Nuclear Medicine, 64(3), 351\u2013354.\u00a0<a href=\"https:\/\/doi.org\/10.2967\/jnumed.123.265420\">https:\/\/doi.org\/10.2967\/jnumed.123.265420<\/a><\/li><li>Mankoff, D., et al. (2024).\u00a0<strong>Summary: SNMMI Procedure Standard\/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16a-[18F]Fluoro-17b-Estradiol PET<\/strong>. Journal of Nuclear Medicine, 65(2), 221\u2013223.\u00a0<a href=\"https:\/\/doi.org\/10.2967\/jnumed.123.266938\">https:\/\/doi.org\/10.2967\/jnumed.123.266938<\/a><\/li><li>Covington, M. F., et al. (2024).\u00a0<strong>18F-Labeled Fluoroestradiol PET\/CT: Current Status, Gaps in Knowledge, and Controversies<\/strong>\u2014 AJR Expert Panel Narrative Review. American Journal of Roentgenology, 223(4).\u00a0<a href=\"https:\/\/doi.org\/10.2214\/AJR.23.30330\">https:\/\/doi.org\/10.2214\/AJR.23.30330<\/a><\/li><li><strong>National Comprehensive Cancer Network (NCCN) Breast cancer Guidelines<\/strong>.\u00a0<a href=\"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\">https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf<\/a><\/li><\/ul><p><b>\u00a0<\/b><\/p><p><b>\u017diadanka je na tejto adrese <\/b><a style=\"font-weight: bold;\" href=\"https:\/\/www.biont.sk\/online-ziadanka\/pet-ct-s-18f-fluorestradiol\/\">18f-fluorestradiol<\/a><b>.<br \/><\/b>V\u00a0pr\u00edpade ot\u00e1zok kontaktujte prim\u00e1ra PET Centra BIONT a. s. <a style=\"background-color: #fbfffe;\" href=\"mailto:povinec@biont.sk\">MUDr. Pavla Povinca, PhD.<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Liek [18F]-Fluoroestradiol Biont vyr\u00e1ba spolo\u010dnos\u0165 BIONT a. s. a\u00a0bude sa pou\u017e\u00edva\u0165 v\u00fdhradne v mieste v\u00fdroby \u2013 v\u00a0zdravotn\u00edckom zariaden\u00ed firmy BIONT, a. s. v\u00a0Bratislave, nako\u013eko m\u00e1 s\u00fahlas MZ SR na skupinov\u00e9 povolenie neregistrovan\u00e9ho lieku.<\/p>\n","protected":false},"author":123461,"featured_media":4448,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48],"tags":[],"class_list":["post-10310","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aktuality"],"_links":{"self":[{"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/posts\/10310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/users\/123461"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/comments?post=10310"}],"version-history":[{"count":16,"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/posts\/10310\/revisions"}],"predecessor-version":[{"id":10362,"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/posts\/10310\/revisions\/10362"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/media\/4448"}],"wp:attachment":[{"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/media?parent=10310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/categories?post=10310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biont.sk\/%77%70%2d%6a%73%6f%6e\/wp\/v2\/tags?post=10310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}